Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Sepsis – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Sepsis – Pipeline Review,…
Represents the Fourth Innovus Pharma Product Notification in the E.U. SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”)…
The company is commercializing its FDA-cleared bio-ConneKt® Wound Matrix to the advance wound care market. ALACHUA, Fla.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/MLMBiologics?src=hash" target="_blank"gt;#MLMBiologicslt;/agt;–UF…
TORTOLA, British Virgin Islands–(BUSINESS WIRE)–Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase…
Enables new sites to participate in the European Phase III SALAMANDER trials LONDON–(BUSINESS WIRE)–Rexgenero, a regenerative medicine company developing advanced…
Transgene confirms that the study’s primary
endpoint (objective response rate – ORR) on a minimum of 35 evaluable
patients will be reported in Q4 2019.
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.
Medicure Inc reported net loss for the quarter ended March 31, 2019 at $2.8 million compared to net income of $1.4 million for the quarter ended March 31, 2018.
Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)
PHILADELPHIA–(BUSINESS WIRE)–Wharton Research Data Services (WRDS), the leading data research platform and business intelligence tool for corporate, academic and government…